Clinical Trials Logo

Geographic Atrophy clinical trials

View clinical trials related to Geographic Atrophy.

Filter by:

NCT ID: NCT05941273 Not yet recruiting - Clinical trials for Age-Related Macular Degeneration

A Study of the SING IMT in an Israeli Cohort

Start date: July 30, 2023
Phase: N/A
Study type: Interventional

The objective of this single center study is to determine the safety of the smaller incision, new generation (SING), implantable miniature telescope (IMT) in a small sample of patients with moderate-severe central vision loss due to late-stage age-related macular degeneration (AMD) in an Israeli Cohort

NCT ID: NCT05893537 Recruiting - Clinical trials for Age-Related Macular Degeneration

Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).

Start date: June 16, 2023
Phase: Phase 2
Study type: Interventional

This is a Phase 2, prospective, multicenter, randomized, double-masked, placebo-controlled 104-week study to assess the efficacy, safety, and tolerability of orally delivered CT1812 compared to placebo in participants with GA associated with dry AMD.

NCT ID: NCT05891275 Completed - Geographic Atrophy Clinical Trials

Patients With Geographic Atrophy and Their Patient Journey in the United States (US)

Start date: May 31, 2023
Phase:
Study type: Observational

To quantify and describe patients with a Geographic Atrophy (GA) diagnosis in at least one eye, and the progression to neovascular Age-Related Macular Degeneration (including how many receive Anti-VEGF), or to GA (in the fellow eye only).

NCT ID: NCT05839041 Recruiting - Clinical trials for Macular Degeneration

A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

SIGLEC
Start date: May 2, 2023
Phase: Phase 2
Study type: Interventional

Investigate the Safety, Pharmacokinetics, and Treatment effects of Single and Multi-dose of Intravitreal AVD-104 in participants with geographic atrophy secondary to age-related macular degeneration.

NCT ID: NCT05811351 Recruiting - Geographic Atrophy Clinical Trials

A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Start date: March 6, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.

NCT ID: NCT05797896 Recruiting - Clinical trials for Macular Degeneration

Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study

i-GAIN
Start date: February 7, 2023
Phase:
Study type: Observational

An observational study to investigate the natural history and evaluate biomarkers of participants with geographic atrophy secondary to age-related macular degeneration

NCT ID: NCT05626114 Recruiting - Geographic Atrophy Clinical Trials

A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Start date: March 24, 2023
Phase: Phase 2
Study type: Interventional

This study will evaluate the success and safety of subretinal surgical delivery as well as the preliminary activity of OpRegen in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). All endpoints are assessed for the study eye unless otherwise indicated.

NCT ID: NCT05536297 Active, not recruiting - Clinical trials for Age-Related Macular Degeneration

Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy

Start date: September 26, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess long-term safety of avacincaptad pegol intravitreal administration for patients with geographic atrophy (GA) who completed Study ISEE2008 (GATHER2) through the Month 24 visit on study treatment (either avacincaptad pegol or Sham).

NCT ID: NCT05481827 Enrolling by invitation - Clinical trials for Age Related Macular Degeneration (AMD)

ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study

ORACLE
Start date: July 12, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the long-term safety of GT005 in participants with Geographic Atrophy (GA) secondary to AMD who have been treated in an antecedent study.

NCT ID: NCT05447650 Recruiting - Clinical trials for Age-Related Macular Degeneration

Microcurrent Stimulation Therapy for Nonexudative Age-related Macular Degeneration (i-SIGHT)

i-SIGHT
Start date: April 12, 2022
Phase: N/A
Study type: Interventional

Evaluate the safety and efficacy of transpalpebral microcurrent stimulation (MCS) therapy for patients with nonexudative (dry) age-related macular degeneration (AMD).